Abstract
There is paucity of data from developing countries on the clinical outcomes in myeloma post-autologous transplantation. In this retrospective study, we used hospital records to retrieve data of patients with multiple myeloma undergoing autologous stem cell transplantation (ASCT) from January 1995 to December 2014 at our centre. During the study period, 245 patients underwent ASCT for myeloma. Of these, 19%, 37% and 37% were in complete response, very good partial response and partial response respectively at the time of ASCT. Only in 14 (5.7%) patients, the stem cells were cryopreserved. The transplant related mortality was 2.86%. The median follow up was 40.7 months (range 0–237.4 months). The 5-year overall survival (OS) and progression-free survival (PFS) for the entire cohort was 61.6% ± 3.8% and 37.2% ± 3.9% respectively. Independent predictors of OS included mononuclear cell dose infused, pre- and post-transplant response; and the use of maintenance therapy. Independent predictors of PFS included age at diagnosis, pre- and post-transplant response; and the use of maintenance therapy. In a resource limited setting, ASCT for myeloma is associated with low transplant related mortality. Pre- and post-transplant response and maintenance therapy are predictors of survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kyle RA, Rajkumar SV (2004) Multiple myeloma. N Engl J Med 351:1860–1873
Altekruse SF, Kosary CL, Krapcho M et al (2007) SEER cancer statistics review. Bethesda, National Cancer Institute
Miguel JFS (2015) Introduction to a series of reviews on multiple myeloma. Blood 125:3039–3040
Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP 3rd (2007) High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transpl 13(2):183–196
Tan D, Chng WJ, Chou T, Nawarawong W, Hwang SY, Chim CS, Chen W, Durie BG, Lee JH (2013) Management of multiple myeloma in Asia: resource-stratified guidelines. Lancet Oncol 14(12):e571–e581
Kumar L, Boya RR, Pai R, Harish P, Mookerjee A, Sainath B, Patekar MB, Sahoo RK, Malik PS, Sharma OD, Gupta R (2016) Autologous stem cell transplantation for multiple myeloma: long-term results. Natl Med J India 29(4):192–199
Malhotra P, Yanamandra U, Khadwal A, Prakash G, Lad D, Law AD, Khurana H, Sachdeva MUS, Bose P, Das R, Varma N, Varma S (2018) Autologous stem cell transplantation for multiple myeloma: single centre experience from North India. Indian J Hematol Blood Transfus 34(2):261–267
Gokarn A, Bonda A, Mathew L, Bagal B, Philip D, Kannan S, Khattry N (2017) High dose chemotherapy with autologous stem cell transplantation for multiple myeloma: outcomes at Tata Memorial Centre. In: Abstract presented at the 16th international myeloma workshop 2017, New Delhi
Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1):3–9
Post MJ, Lass-Floerl C, Gastl G, Nachbaur D (2007) Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 9(3):189–195 Epub 19 May 2007 PubMed PMID: 17511828
Pagano L, Caira M, Nosari A, Van Lint MT, Candoni A, Offidani M, Aloisi T, Irrera G, Bonini A, Picardi M, Caramatti C, Invernizzi R, Mattei D, Melillo L, de Waure C, Reddiconto G, Fianchi L, Valentini CG, Girmenia C, Leone G, Aversa F (2007) Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study—sorveglianza epidemiologica infezioni fungine nelle emopatie maligne. Clin Infect Dis 45(9):1161–1170 Epub 26 Sep 2007 PubMed PMID: 17918077
Teh BW, Teng JC, Urbancic K, Grigg A, Harrison SJ, Worth LJ, Slavin MA, Thursky KA (2015) Invasive fungal infections in patients with multiple myeloma: a multi-center study in the era of novel myeloma therapies. Haematologica. 100(1):e28–e31. https://doi.org/10.3324/haematol.2014.114025. Epub 10 Oct 2014 PubMed PMID: 25304609; PubMed Central PMCID: PMC4281332
Marchesi F, Mengarelli A, Giannotti F, Tendas A, Anaclerico B, Porrini R, Picardi A, Cerchiara E, Dentamaro T, Chierichini A, Romeo A, Cudillo L, Montefusco E, Tirindelli MC, De Fabritiis P, Annino L, Petti MC, Monarca B, Arcese W, Avvisati G (2014) Rome Transplant Network. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome transplant network. Transpl Infect Dis 16(1):158–164. https://doi.org/10.1111/tid.12162 Epub 12 Nov 2013 PubMed PMID: 24215479
Auner HW, Szydlo R, Hoek J, Goldschmidt H, Stoppa AM, Morgan GJ et al (2015) Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years. Bone Marrow Transpl 50(2):209–215
Saad A, Mahindra A, Zhang MJ, Zhong X, Costa LJ, Dispenzieri A et al (2014) Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transpl 20(3):402–408.e1
Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN (2015) American society for blood and marrow transplantation. Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American society for blood and marrow transplantation. Biol Blood Marrow Transpl 21(7):1155–1166
Moreb JS, Byrne M, Shugarman I, Zou F, Xiong S, May WS, Norkin M, Hiemenz J, Brown R, Cogle C, Wingard JR, Hsu JW (2018) Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. J Clin Apher 33(1):29–37
Vij R, Kumar S, Zhang MJ, Zhong X, Huang J, Dispenzieri A, Abidi MH, Bird JM, Freytes CO, Gale RP, Kindwall-Keller TL, Kyle RA, Landsburg DJ, Lazarus HM, Munker R, Roy V, Sharma M, Vogl DT, Wirk B, Hari PN (2015) Impact of pretransplant therapy and depth of disease response before autologous transplantation for multiple myeloma. Biol Blood Marrow Transpl 21(2):335–341
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All the authors declare that they have no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Since this was a retrospective study, the institutional review board granted a waiver of consent.
Rights and permissions
About this article
Cite this article
Kulkarni, U., Devasia, A.J., Korula, A. et al. Clinical Outcomes in Multiple Myeloma Post-Autologous Transplantation—A Single Centre Experience. Indian J Hematol Blood Transfus 35, 215–222 (2019). https://doi.org/10.1007/s12288-018-0989-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-018-0989-y